Medicare Spending on Ozempic and Other GLP-1s Is Skyrocketing

This policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years. Medicare is prohibited from covering drugs used for weight loss, but Medicare Part D plans can cover GLP-1s for their other medically-accepted indications, including to treat diabetes.

Read the full post on Reports on Health Insurance and Health Care Costs from the Kaiser Family Foundation